Market Cap (In USD)
2.32 Million
Revenue (In USD)
-
Net Income (In USD)
-5 Million
Avg. Volume
5.44 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.452-1.87
- PE
- -0.27
- EPS
- -1.13
- Beta Value
- 0.25
- ISIN
- US74365N2027
- CUSIP
- 74365N103
- CIK
- 1022899
- Shares
- 7525680.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Garo H. Armen Ph.D.
- Employee Count
- -
- Website
- https://www.protagenic.com
- Ipo Date
- 2021-04-27
- Details
- Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
More Stocks
-
REKAReka Industrial Oyj
REKA
-
ADIAAdia Nutrition, Inc.
ADIA
-
001203
-
CNE
-
PBH
-
PVEG
-
1650
-
NPFC